2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
41
Non-Muscle Invasive Bladder Neoplasms
25
Colorectal Neoplasms
21
Carcinoma, Transitional Cell
17
Anus Neoplasms
17
Neoplasm Metastasis
12
Carcinoma, Hepatocellular
11
Appendiceal Neoplasms
11
Stomach Neoplasms
10
Peritoneal Neoplasms
9
Pancreatic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
7
Lung Neoplasms
6
Colonic Neoplasms
6
Rectal Neoplasms
5
Liver Neoplasms
5
Urologic Neoplasms
4
Sarcoma
4
Carcinoma
4
Anal Canal Carcinoma
4
Urologic Diseases
3
Urogenital Neoplasms
3
Urinary Bladder Diseases
3
Recurrence
3
Pseudomyxoma Peritonei
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Mesothelioma, Malignant
3
Gastrointestinal Neoplasms
3
Interventions
atezolizumab
2
Gemcitabine
2
Cell Count
2
ziprasidone
1
valrubicin
1
tretazicar
1
pembrolizumab
1
liposomal doxorubicin
1
fludarabine phosphate
1
fludarabine
1
enadenotucirev
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Vaccines
1
Tumor Necrosis Factor-alpha
1
Tranexamic Acid
1
Tobramycin
1
Spironolactone
1
Sevelamer
1
Rocuronium
1
Radiotherapy
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Oncolytic Virotherapy
1
Nifedipine
1
Nafcillin
1
Molindone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoviridae Infections
×
Mitomycin
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled